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ABSTRACT
CHARACTERIZATION OF THE GROWTH FACTOR RECEPTOR NETWORK
ONCOGENES IN LUNG CANCER
by Ashley H. Duche

Lung cancer remains the leading cause of cancer related deaths worldwide, reportedly
contributing to 1.8 million of the 10.0 million mortalities documented in the year 2020. Although
advancements have been made in therapeutics and diagnostic methods, formulation of effective
treatments and development of drug resistance continues to be a challenge. These challenges arise
from our lack of understanding of intricate signaling pathways, such as the Growth Factor Receptor
Network (GFRN), which contributes to complex lung tumor heterogeneity allowing for drug
resistance development. In this study, gene expression signatures of six GFRN oncogenes
overexpressed in human mammary epithelial cells (HMECs) were generated to interrogate this
pathway’s downstream crosstalk, beyond initial mutation status. Utilization of this method may
reveal novel phenotypic patterns that could be used to improve targeted therapies for lung cancer.
Thus, using computational analysis tools, gene expression signatures were generated of BAD
(BAD), HER2 (ERBB2), IGF1R (IGF1R), RAF (RAF1), and KRAS (G12V), using the Bioconductor
package, Adaptive Signature Selection and InteGratioN (ASSIGN). Gene lists of various lengths
were generated ranging from 5 to 500 genes produced in 25 gene increments. Pathway activation
estimates were predicted in 541 lung adenocarcinoma (LUAD) tumors acquired from The Cancer
Genome Atlas (TCGA). Each gene signature underwent validation using proteomics data from
The Cancer Proteome Atlas (TCPA) and gene expression. Following thorough analysis, optimal
gene signatures were determined for the genes BAD, HER2, IGF1R, RAF and KRAS. In all, the
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optimized GFRN pathway-specific gene signatures were able to distinguish upregulated pathway
activity within TCGA patient tumor samples. With the use of drug response data, novel phenotypic
patterns may be revealed identifying drug targets to improve individualized drug targeted therapy
for lung cancer.
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“The greatest enemy of knowledge is not ignorance, it is the illusion of knowledge.”
Stephen Hawking
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CHAPTER 1
INTRODUCTION
Lung cancer remains the leading cause of cancer related deaths despite progressive
advancements in therapeutic and diagnostic methods worldwide. According to the American
Cancer Society (ACS), it is estimated that of the 608,570 cancer related mortalities projected to
occur in the United States in 2021, 131,880 cases will be due to lung cancer [1]. Similar to other
cancers, lung tumors develop due to epigenetic factors causing genetic alterations, such as somatic
mutations, gene amplifications and chromosomal rearrangements/translocation, affecting a cell's
regulatory mechanisms and normal functions[1, 2]. With traditional methods, lung tumors can be
classified into two major types, including small cell lung cancer (SCLC) and non-small cell lung
cancer (NSCLC)[3]. Within NSCLC there are three main subtypes - squamous cell carcinoma,
adenocarcinoma, and large cell carcinoma. Although through the advancements of diagnostic
methods with the incorporation of molecular profiling, further tumor heterogeneity has emerged
revealing diversification of lung tumors within the same histological subtype [2]. Such molecular
profiling methods include immunohistochemistry (IHC), chromogenic/fluorescence in situ
hybridization (CISH/FISH), next-generation sequencing, sanger and pyrosequencing, as well as
quantitative polymerase chain reaction (qPCR) and fragment analysis (FA/Frag.Analysis) [4].
These methods allow for specific genetic alterations, referred to as biomarkers, to be identified
within a tumor and used to make improved diagnosis, prognosis and therapeutic treatments.
Although, a challenge continually faced is targeted mutations do not always respond to oncological
treatments and consequently form mechanisms that allow resistance to therapeutic treatments [5].
This can result from unknown downstream signaling that remains uncharacterized in complex
oncogenic networks such as the Growth Factor Receptor Network (GFRN) [7].
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1.1 Overview
The GFRN is a known driving oncogenic network in lung cancer consisting of parallel
signaling pathways responsible for regulating developmental and growth processes within the cell
(Figure 1.1) [6]. Two stimulated growth factor pathways comprising of this network include the
phosphatidylinositol-3-kinase (PI3K)/protein kinase B (AKT)/ mechanistic target of rapamycin
kinase (mTOR) as well as the RAS/serine-threonine protein kinase (RAF)/ mitogen-activated
protein kinase (MAPK) pathway [7, 8]. The PI3K/AKT/mTOR pathway is commonly associated
with NSCLC responsible for controlling cell survival, metabolism and proliferation [7]. Within
this pathway, upstream activation of receptor tyrosine kinases (RTKs) such as EGFR, HER2, and
insulin-like growth factor receptor (IGF1R), initiates a complex signaling cascade leading to the
activation of PI3K lipid kinases [7]. A signal is then relayed resulting in the activation of AKT, in
turn activating serine/threonine (Ser/Thr) kinase mTOR [9]. Many negative feedback regulators
are associated with this pathway such as the inactivation of AKT through phosphatase and tensin
homolog (PTEN) tumor suppressor, as well as the inhibition of IGF1R signaling by downstream
products of mTOR [9]. To bypass these negative feedback mechanisms, the PI3K/AKT/mTOR
pathway interacts with the neighboring pathway RAS/RAF/MAPK [9, 10]. The RAS/RAF/MAPK
pathway is also associated with tumorigenesis initiated through the phosphorylation of RTKs, such
as EGFR [9]. Following receptor mediated activation, a signaling cascade is initiated activating
the GTPase protein KRAS, transmitting a signal activating the Ser/Thr-protein kinase RAF1, also
known as c-RAF [10]. Subsequent activation leads to phosphorylation of MEK1/2 resulting in
activation of Ser/Thr kinases, ERK1/ERK[8, 10]. What ultimately makes this pathway difficult for
formulation of effective drug targeted treatments is the alternate pathway activation that can occur
between these parallel signaling pathways. For instance, alternate pathway activation of PI3K can
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be transduced through RAS signaling, mTOR can be activated through ERK, and AKT can inhibit
activation of RAF as well as BAD (BCL2 Associated Agonist of Cell Death)[11, 12]. Therefore,
simultaneous characterization of the GFRN is warranted for applying targeted therapies in lung
cancer.

To begin to characterize the network of complex signaling pathways within lung cancer,
gene expression signatures can be utilized to interrogate GFRN activity within lung tumors. A
gene expression signature is a gene, or a combined group of genes expressing aberrant or normal
pathway activity associated with causing a disease or biological process [13, 14]. Signatures
consist of selected genes quantitatively expressing varying levels of gene expression in respect to
the biological state of the pathway being explored [13, 14]. They can be used to represent a
single pathway or be leveraged in conjunction to explore multiple activated pathways
simultaneously [5]. This allows for a comprehensive profile of interconnecting signaling networks
to be explored which can potentially be used to make improved prognostic, diagnostic, and
therapeutic treatment decisions [6].

In summary, the utilization of generated gene expression signatures can be leveraged to
explore complex signaling pathways using selected genes of possible significance to reveal
underlying molecular mechanisms of a disease. Applying this concept, the objective of my
research was to generate GFRN pathway-specific gene expression signatures of the pathways BAD
(BAD), HER2 (ERBB2), IGF1R (IGF1R), RAF (RAF1), and KRAS (KRAS, G12V mutation). It was
hypothesized that if pathway-specific gene expression signatures of GFRN activity can be
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generated, representing the oncogenic state of that pathway, GFRN activity can be characterized
within lung tumors to reveal novel phenotypic patterns to make drug response predictions.

1.2 Relevance of Exploration for Selected GFRN Oncogenes
Proven by previous studies, the GFRN has played a critical role in driving oncogenic
processes leading to lung tumor formation. As referenced in Figure 1, the pro-apoptotic protein
BAD, is one of the many signaling pathways comprising this network. BAD plays an important
role in promoting apoptotic cell death, which has made it a predictive biomarker within lung
cancer[11, 12]. Low levels of BAD expression have been associated with tumorigenesis across
many other cancers as well, indicating its importance in anti-cancer cellular functions [11].
Inhibition of this pathway, as previously mentioned, stems from the activation of PI3K signaling
activating AKT, which in turn inhibits the pro-apoptotic protein [6, 7, 12]. Having the knowledge
of BAD’s anticancer characteristics, and its role in tumor progression, studies have suggested that
overexpression of this protein can also allow BAD to act as a tumor suppressor [11, 12]. This
makes BAD a promising target for future use of formulating effective therapeutic treatments.

Another associated GFRN pathway is the protein tyrosine kinase HER2. HER2 is a cell
surface receptor associated with PI3K pathway activation initiating tumorigenesis [15]. In recent
studies, the presence of HER2 mutations within NSCLC patients may be correlated with lower
survival rates [15, 16]. Additionally, utilization of molecular profiling methods may have revealed
further intrinsic subtypes, showing a correlation with HER2 mutations with the presence of EGFR
mutations, and ALK translocations[9, 15, 16]. Although there has been conflicting evidence of
HER2’s involvement in lung cancer making further exploration of this pathway essential.
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In addition to BAD and HER2, another GFRN pathway associated with lung tumor
development is IGFR. This RTK has shown correlations of overexpression linked to increased cell
survival and proliferation of malignant cells [17]. Acquired resistance to therapies such as gefitinib
and erlotinib have been observed with possible intrinsic subtypes such as the presence of EGFR
mutations as well as ALK arrangements, similar to HER2 [17]. Additionally, IGF1R intrinsic
subtypes may have also been correlated with the development of resistance to EGFR targeted
treatments[17]. Benefits of further exploration of this pathway may lead to the development of
effective therapeutic treatments against EGFR drug resistance mechanisms using molecular
profiling to reveal cancer promoting cellular mechanisms.

As revealed in prior studies, the proto-oncogene RAF, has shown associations with the
RAS signaling pathway within the GFRN [10]. Also known as RAF1 or c-RAF, the full
characterization of this pathway’s activation remains unclear, as well as its role in lung tumor
development [10]. Although, studies have supported c-RAF activation is required for the initiation
of tumorigenesis through KRAS transduction [10]. Within lung cancer, the development of KRAS
drug resistance has continually been a challenge due to the ineffectiveness of current therapeutic
treatments, as well as efficacy issues with targeted treatments of ERK/MAPK inhibition[10].
Possible leverage of targeting the c-RAF pathway, as well has further exploration revealing its
molecular mechanisms, mays be used to develop novel effective treatments targeting KRAS with
reduced drug resistance development.
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Previously mentioned, a common mutation associated with lung cancer development is the
RAS Family, proto-oncogene KRAS. Various variants of KRAS mutations have been identified
including G12C, G12B, and G12V, classified based upon their amino acid substitution. The
significant prevalence of this mutation within lung cancer presses the need for effective therapeutic
treatments. Although, due to the complex signaling and alternate pathway activations, formulation
of effective therapeutic treatments continues to be a challenge (Figure 1.1)[10, 18]. In an attempt
to formulate targeting treatments for KRAS combating drug resistance development, exploration
of coinciding mutations has been performed in previous studies[18]. Possible associations between
the presence of KRAS coinciding with EGFR was revealed but little significance was observed
pertaining to prognosis [18]. Although, additional studies have showed promise applying this
method leading to further subtyping of KRAS using co-existing mutations revealing novel drug
susceptible targets.

In all, our lack of understanding of underlying GFRN molecular mechanisms and intricate
signaling pathways, stems our need for enhanced characterization methods such as gene expression
signature exploration. Through the utilization of this method, a comprehensive profile of the
GFRN, beyond initial mutation status, can begin to be developed and utilized to improve current
therapeutic treatments to fight the development of drug resistance observed in lung cancer.
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CHAPTER 2
METHODS

2.1 Generation of GFRN-Specific Gene Expression Data
To begin GFRN pathway analysis, previously processed RNA sequencing gene expression
data generated from a published study was acquired [6]. Briefly, the cells used to produce the
biological replicates were human mammary epithelial cells (HMECs) acquired from noncancerous breast tissue. HMECs were transfected using recombinant adenovirus of GFRN-specific
oncogenes BAD (BAD), HER2 (ERBB2), IGF1R (IGF1R), RAF (RAF1), and KRAS (G12V) to
capture a transcriptional profile of aberrant pathway activity. Cells used to produce the biological
replicates were produced using 0.25% serum-free mammary epithelial basal medium (MEBM) in
conjunction with a Lonza “bullet kit” as referenced in the protocol [7]. HMECs expressing GFRN
oncogenes BAD (BAD), HER2 (ERBB2), IGF1R (IGF1R), RAF (RAF1) or GFP (control) were
incubated for 18 hours to capture the initial transcriptional profile. HMECs transfected with KRAS
(G12V) along with its GFP respective controls were treated for 36 hours. Western blot analysis
was then performed using corresponding protein antibodies to each GFRN oncogene to ensure
successful overexpression of GFRN oncogenes within HMECs. Following validation mRNA was
extracted from cells to generate 6 biological replicates for BAD (BAD), IGF1R (IGF1R), and RAF
(RAF1), with 5 produced for HER2 (ERBB2). For the separately treated HMECs expressing KRAS
(G12V), 9 biological replicates were produced along with 9 GFP respective controls. The generated
biological replicates of the overexpressed GFRN oncogenes from HMECs were then sequenced
and aligned computationally using Rsubread R package (Version 1.14.2) to produce the gene
expression RNA-Seq datasets.
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2.2 Obtained RNA Sequencing Datasets
To begin gene signature generation and analysis, various databases were used to acquire
the publicly available RNA-sequencing data (Table 2.1). From the National Center for
Biotechnology Information (NCBI), Gene Expression Omnibus (GEO), the previously mentioned
gene expression data was collected containing the 6 overexpressed GFRN oncogenes and their
respective controls from 2 separate datasets [7]. The first dataset included the genes BAD (BAD),
HER2 (ERBB2), IGF1R (IGF1R), RAF (RAF1), with the GFP samples (the control) treated for 18
hours (GSE83083). The second dataset included the gene KRAS (G12V) with GFP samples (the
control) treated for 30 hours (GSE83083). From TCGA, 541 LUAD patient tumor samples were
collected along with a separate dataset used to classify and specify the cancer type (GSM1536837,
GSE62944). Lastly, to perform validation, proteomics data was collected from TCPA.

2.3 Data Refinement
Utilizing the prcomp function from the stats R package, the collected gene expression data
along with the TCGA patient tumor samples, were visualized using Principal Component Analysis
(PCA) within Rstudio (Version 1.2.5019) (Figure 2.1 a-d). PCA is a statistical procedure used to
produce principal components representative of the greatest variation occurring in the
multidimensional data [12]. The first principal component produced represents the greatest
variation, while the second represents the second greatest variation in the multidimensional data
and so on (Figure 2.1 a and c) [12]. Due to the datasets being separately processed, significant
batch effects and confounding variables were observed (Figure 2.1 a-b). This could be due to many
external factors, such as tissue mishandling when producing the samples, varying lab protocols
and conditions, as well as human error. Such variability can negativity affect the generation of our
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signatures and its ability to predict pathway activity within the tumor samples. To begin to reduce
variations, the datasets underwent refinement to remove technical artifacts from the gene
expression datasets. This included filtering of rows containing a certain percentage of zero values
to capture genes with most variance in the dataset. PCA was then utilized throughout the study to
ensure optimization of the data and signature generation.

2.4 Batch Adjustment
Following refinement of the RNA seq. data, the significant variances and confounding
batch effects were adjusted for using the ComBat function from sva R package (Version 3.34.0)
and visualized using PCA (Figure 2.1 c-d). This included specifying the gene expression data and
patient tumor samples into 3 separate batches and performing a two-step batch adjustment. First,
the appropriate training model was specified which included the 6 biological replicates for each
oncogene including BAD (BAD), IGF1R (IGF1R), RAF (RAF1) and 5 for HER2 (ERBB2); along
with its 12 GFP controls treated for 18 hours (control). The second batch, also specified as the
training data, included the 9 biological replicates for KRAS (G12V) with its respective 9 GFP
replicates, pre-treated for 36 hours (control). The first batch adjustment was then performed only
including the training data, with the first batch specified as the reference used to compare and
optimize data similarity. Following the first adjustment, the third batch was then specified as the
541 LUAD patient tumor samples from TCGA, classified as the test data. The second combat
adjustment was then performed using the combat adjusted gene expression data (training data)
combined with the TCGA patient tumor sample (test data) with the first batch selected as the
reference batch. A PCA was then performed to confirm variances and confounding batch effects
were removed to improve data similarity (Figure 2.1 c-d).
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2.5 Gene Expression Signature Generation
With the adjusted data, gene expression signatures were generated representing pathway
specific GFRN activity. This was performed using the “All-in-one” assign.wrapper function from
the “semi-supervised pathway profiling toolkit”, Adaptive Signature and InteGratioN (ASSIGN;
Version 1.9.1). Within each pathway-specific gene expression signature, genes quantitatively
expressing varying levels of expression were selected by ASSIGN to define a phenotypic pattern
representative of aberrant GFRN-specific pathway activity. This included creating two distinctive
patterns of expression within the signature to represent pathway activity turned on versus pathway
activity turned off. For each GFRN specific pathway, this was produced internally by comparing
the GFP gene expression data (control) to the specified overexpressed oncogene expression data.

2.6 ASSIGN Gene Expression Signature Output
Various gene lists of specified lengths were then generated ranging from lengths of 5 to
500 genes produced in 5 or 25 gene increments using the assign.wrapper function; utilizing a single
pathway setting. The Bayesian variable selection approach was used to select genes expressing the
greatest fold-change of differential expression from normal pathway activity to generate the
signature. These genes selected displayed the highest signal strength and signal weights
representing their possible contribution to the overall development of the disease. Additionally, an
anchor gene was selected for the genes as follows BAD (BAD), HER2 (ERBB2), IGF1R (IGF1R)
RAF(RAF1), and KRAS (KRAS). This ensures the overexpressed oncogene specific to the pathway
being investigated is included in each gene signature output. Additional ASSIGN criteria were also
specified including adaptive signature background parameters. This included the adaptive_B =
TRUE, default parameter, which allows ASSIGN to adjust the test data baseline measures. Next,
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adaptive_S = FALSE was specified, preventing the adaptability of the gene signatures to adhere
to the test data. Additional default parameters were also included specifying probability measures
such as p_beta = 0.01, theta0=0.05, theta1=0.9. Next, the iteration was increased from the default
parameter of iter = 2,000 to iter = 100,000 to increase the number of Markov Chain Monte Carlo
(MCMC) simulations. Lastly, the number of burn-in iterations was increased from the default of
burn_in = 1,000 to burn_in = 50,000 to optimize gene signature output. From the produced output,
those that passed the internal leave-one-out cross validation (LOOCV) then underwent external
validation using proteomics and gene expression data.

2.7 External Validation
Using the cor.test function from the stats package (Version 4.0.3) correlations were
performed to validate the generated pathway activation estimates from ASSIGN. First, using
proteomics data, Pearson pairwise correlations were calculated between Reverse Phase Protein
Array (RPPA) data from The Cancer Proteome Atlas (TCPA) with the generated pathway
activation estimates. This was performed using the cor.test function from the R stats package
(Version 4.0.3), using the Pearson method. Pathway activation estimates were considered to be
validated if the “Pearson’s product moment”, calculated using a 95% confidence interval, had a padjusted value of < 0.002. The p-adjusted value was calculated due to the high quantity of TCGA
patient tumor samples. The same parameters and cor.test function were used to validate the
pathway activation predictions correlated to the TCGA patient tumor sample gene expression data.
Lastly, using the function boxplot2 from the package gplots (Version 3.1.1), boxplots were
produced expressing predicted pathway activity levels within the TCGA patient tumor samples.
The data was first scaled to optimize boxplot generation along with specification of pathway
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activity levels by low, intermediate, and high percentiles. Samples with expression in the 10th
percentile or below were classified as “low” expressing. Samples with expression in the 90th
percentile or above were classified as “high” expressing. Samples with the expression above the
10th percentile and below the 90th percentile were classified as “intermediate” expressing samples.
Pathway-specific boxplots were considered to be validated if higher predicted pathway activity
could be seen within the patient tumor samples categorized in the “high” expressing percentile in
comparison to the “intermediate” and “low” expressing percentiles.

CHAPTER 3
RESULTS

3.1 Pathway-Specific Gene Expression Signature Generation
With the use of RNA sequencing data of HMECs overexpressing GFRN oncogenes, gene
expression signatures of varying gene list lengths were generated using Rstudio (Version 1.2.5019)
(Table 3.1-3.5). Pathway activation estimates were also produced by projecting the signatures onto
the 541 LUAD patient tumor samples to predict levels of pathway activity. These signatures were
produced by comparing the overexpressing HMECs to its respective GFP (control) HMEC
samples. To ensure the signatures’ ability to capture the levels of pathway activity are expressed
within the HMEC samples, pathway-specific cross-validation scatterplots of the training data was
assessed. Produced scatterplots of each GFRN pathway-specific oncogene that accurately
displayed low levels or no level of pathway activity for GFP (control) versus high levels of activity
for the overexpressed GFRN HMECs were considered to be internally validated. This included the
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gene lists lengths with the corresponding GFRN pathway being investigated as follows BAD
(BAD), 475; HER2 (ERBB2), 5; IGF1R (IGF1R), 25; RAF (RAF1), 275; and KRAS (KRAS, G12V),
500 (Table 3.1-3.5). External validation was then performed using proteomics and gene expression
data to determine if the generated gene expression signatures accurately predicted levels of
pathway activity within the LUAD patient tumor samples from TCGA.

3.2 Proteomics Validation
First, using proteomics data from TCPA pathway activation estimates were validated
through statistical analysis. This included performing Pearson pairwise correlations between the
produced pathway-specific gene expression signatures and their predicted pathway activity to
RPPA protein expression data from TCPA (Table 3.6). For the signature validation of BAD, the
TCPA protein expression of PDK1_pS241 phosphoprotein was correlated to the predicted levels
of pathway activation for BAD. Due to the upstream signaling of PDK1 leading to the activation
AKT which in turn inhibits BAD, negative correlations were observed as anticipated. Strongest
negative correlations for BAD were most optimally seen using the 475-gene signature list (cor = 0.247206, p-value = 1.63E-06, optimal gene list = 475). For the signature validation of HER2, the
phosphoprotein HER2_pY1248 showed a strong positive correlation to the predicted pathway
activity using the 5-gene signature list (cor = 0.3180165, p-value =4.54E-10, optimal gene list =
5). Next, for RAF the phosphoprotein of CRAF_pS338 showed a significant positive correlation
using the 275-signature gene list (cor = 0.3176497, p-value = 4.77E-10, optimal gene list = 275).
Lastly, for the signature validation of KRAS the phospho-protein MEK1_pS217S221 was utilized
due to downstream activation of MEK1 as a consequence of KRAS upstream activation. The
highest positive correlation was observed using the KRAS 500-gene signature list (cor =
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0.1643924, p-value = 0.001577, optimal gene list = 500). All gene expression signatures were able
to be validated using protein expression levels, except for IGF1R, as referenced in Table 3.6.

3.3 Gene expression Validation
Next, Pearson pairwise correlations were performed between the signature predicted
pathway activity of the respective GFRN pathway to the expression levels of the gene of interest
within the LUAD patient tumor samples from TCGA (Table 3.7). For the validation of BAD, the
estimated pathway levels predicted by the BAD 475- gene signature showed a positive correlation
to the patient samples expressing higher levels of bad activity indicating accurate signature
predictability (cor = 0.1127843, p-value = 0.008649, optimal gene list = 475). Next, for HER2
validation, the 5-gene signature showed a strong positive correlation to HER2 mutated levels of
activity within the patient tumor samples (cor = 0.4114047, p-value = < 2.2e-16, optimal gene list
= 5). Lastly, IGF1R was validated using the IGF1R oncogene test gene expression with the
strongest positive correlation being seen using the 25-gene signature list (cor = 0.178464, p-value
= 2.98E-05, optimal gene list = 25). Overall, with the corresponding oncogene expression from
the patient tumor samples, the pathways BAD, HER2, and IGF1R were validated with the
exceptions of RAF and KRAS, summarized in Table 3.7.

3.4 Gene Expression Boxplot Validation
Additionally, gene expression box plots were generated to distinguish levels of pathway
activity within patient tumor samples using the predicted pathway activity levels from the gene
expression signatures (Figure 3.1). As mentioned, prior, patient tumor samples were classified into
“low”, “intermediate”, and “high” percentiles based upon their levels of expression. As

14

summarized in Table 3.8 and Figure 3.1, this method was able to validate the GFRN pathways
BAD, HER2, IGF1R with the exception of RAF and KRAS.

3.5 Optimal Gene Signature Selection
In all, optimal gene list lengths were determined through statistical analysis by cross
referencing proteomics and gene expression correlations (Table 3.8). For the GFRN pathway
BAD, proteomics, gene expression, and gene expression box plots validated the 475-signature
gene list (Table 3.1). For HER2, all three methods were also used to validate the HER2’s 5signature gene list (Table 3.2). Next, for IGF1R, only the gene expression and generated gene
expression boxplot was used for validation of the 25-signature gene list (Table 3.3). For the GFRN
RAF, only protein expression was used for the validation of its 275- signature gene list (Table 3.4).
Lastly, for KRAS, only protein expression was used for the validation of the 500-signature gene
list (Table 3.5).
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CHAPTER 4
DISCUSSION

4.1 Significance of Findings and Future Implications
In this study, GFRN-specific gene expression signatures, represented of aberrant pathway
activity, were generated to interrogate GFRN pathway activity within lung tumors. Optimal gene
expression signatures were then determined for the GFRN pathways BAD (BAD), HER2 (ERBB2),
IGF1R (IGF1R), RAF (RAF1), and KRAS (G12V) using proteomics and gene expression
data (Figure 4.1). For the signatures HER2(ERBB2), IGF1R(IGF1R), RAF(RAF1) and
KRAS(G12V), predicted pathway activity showed a positive correlation with downstream protein
expression levels, indicating downstream pathway activation of the investigated pathways. For the
signature BAD, protein expression representing downstream activation of the AKT pathway,
activated upstream by PDK1, showed corresponding negative correlations indicating inhibition of
the BAD pathway activity, as anticipated. Next, corresponding higher levels of gene expression
were observed in HER2 and IGF1R when correlated with mutated levels of gene expression
supporting aberrant pathway activation of the two pathways. In addition, upregulated levels of
AKT pathway activity were used to validate BAD’s signature representing abnormal pathway
activity, in which negative correlations were seen, accurately depicting the inhibition of BAD by
AKT activation. In addition, boxplots were used to validate signature generation for the pathways
BAD, HER2, and IGF1R. A percentage of the tumor samples were distinguished to have higher
levels of pathway activity signifying the gene expression signatures ability to characterize mutated
levels of pathway activity. In all, it was concluded that the generated GFRN-pathway specific gene
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expression signatures, representative of aberrant GFRN activity, accurately distinguished higher
levels of pathway activity within LUAD patient tumor samples.

In future studies, a multiple pathway analysis will be performed using the generated gene
expression signatures to begin to comprehend underlying molecular mechanisms of the GFRN.
Through the projection of these signatures, simultaneously onto lung cancer cell lines, hierarchical
clustering can be utilized to reveal patterns of gene expression. These gene expression patterns, or
phenotypic patterns, can be characterized to reveal drug sensitive or resistant phenotypes by
performing drug response predictions. Potential intrinsic subtypes could also be revealed exposing
sensitivity patterns within this complex network. Overall, with the use of multiple-pathway
analysis with the GFRN pathway-specific gene expression signatures, a potential comprehensive
profile of the GFRN can be built to reveal novel phenotypic patterns and identify drug sensitivities.
This in turn, can be used to enhance prognostic, diagnostic, and therapeutic treatment decisions
against lung cancer, overall enhancing precision medicine approaches to combat drug resistance
development.
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Table 2.1 Publicly available datasets acquired for gene signature generation and analysis consisting of
gene expression signature data along with LUAD patient tumor samples and proteomics validation
dataset.
Dataset

Source

Content

Accession
GSE83083

NCBI
GEO

Gene expression data of overexpressed HMECs
• GFP18: 6 controls
IGF1R: 6 samples
• BAD (BAD): 6 samples
RAF (RAF1): 6
samples
• HER2(ERBB2): 5 samples

Accession
GSE83083

NCBI
GEO

Gene expression data of overexpressed HMECs
• GFP30: 9 controls
• KRAS_GV (G12V): 9 samples

Accession
GSE59765

NCBI
GEO

Gene expression data of overexpressed HMECs:
• Control: 6 EGFR controls
• EGFR (EGR1): 6 samples

Accession
GSM1536837

NCBI
GEO

TCGA Patient Tumor Samples gene expression:
• LUAD: 541 samples

Accession
GSE62944

NCBI
GEO

TCGA Cancer Type Samples TCGA tumor sample barcode with
corresponding sample classification.

_____

TCPA

Proteomics expression levels of corresponding GFRN
downstream pathway activations.
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Table 3.1 Optimal signature gene list generated for BAD pathway listing all 475 genes and their
associated weight in the signature in predicting BAD pathway activity.
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Table 3.2 Optimal signature gene list generated for HER2 pathway listing all 5 genes and their associated
weight in the signature in predicting HER2 pathway activity.

Table 3.3 Optimal signature gene list generated for IGF1R pathway listing all 25 genes and their
associated weight in the signature in predicting IGF1R pathway activity.
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Table 3.4 Optimal signature gene list generated for RAF pathway listing all 275 genes and their associated
weight in the signature in predicting RAF pathway activity.
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Table 3.5 Optimal signature gene list generated for KRAS pathway listing all 500 genes and their associated
weight in the signature in predicting KRAS pathway activity.

26

27

28

29

Table 3.6 Optimal gene list selection using proteomics validation calculated with Pearson pairwise
correlations between predicted pathway activations and TCPA protein expression levels.
Pathway
List length
Antibody
cor
p-value
BAD

475

PDK1_pS241

-0.247206

1.63E-06

HER2

5

HER2_pY1248

0.3180165

4.54E-10

IGF1R

25

IGF1R_pY1135Y1136

x

x

RAF

275

CRAF_pS338

0.3176497

4.77E-10

KRAS

500

MEK1_pS217S221

0.1643924

0.001577

Table 3.7 Optimal gene list selection using gene expression validation calculated with Pearson pairwise
correlations between predicted pathway activations and TCGA patient tumor expression levels.
Pathway
List length
Validation Gene
cor
p-value
BAD

475

BAD

x

x

HER2

5

ERBB2

0.4114047

< 2.2e-16

IGF1R

25

IGF1R

0.178464

2.98E-05

RAF

275

RAF1

x

x

KRAS

500

KRAS

x

x

Table 3.8 Summary table of gene signature selection and methods used for validation.
Pathway
Oncogene List length Proteomics
Gene

Box plot

BAD

BAD

475

PDK1_pS241

BAD

✔️

HER2

ERBB2

5

HER2_pY1248

ERBB2

✔️

IGF1R

IGF1R

25

x

IGF1R

✔️

RAF

RAF1

275

CRAF_pS338

x

x

KRAS

G12V

500

MEK1_pS217S221

x

x
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Figure 1.1 Schematic overview of the driving oncogenic Growth Factor Receptor Network (GFRN)
responsible for cell survival, growth, and metastasis. Consist of two intercommunicating parallel signaling
pathways including RAS/RAF/MAPK pathway, shown in green, and the PI3K/AKT/mTOR, shown in blue.
RAS pathway activation can be initiated by EGFR receptor mediated signaling leading to activation of
RAF, in turn initiating MEK activation, as a result initiating tumorigenesis through ERK activation. Its
neighboring pathway PI3K can be initiated through HER2(ERBB2) receptor mediated signaling as well as
RAS activation. This then results in the inactivation of PDK1 activating AKT signaling which can inhibit
the BAD pathway and/or lead to activation of mTOR resulting in tumorigenesis. Additional, signaling
pathways can be initiated such as the inhibition of ERK leading to inhibition of RAF through mTOR
activation. Although various alternate pathways of activation leading to drug resistance remain
uncharacterized.
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(b)
Principal Component 2

(a)

Principal Component 1

(d)
Principal Component 2

(c)

Principal Component 1

Figure 2.1 (a)Principal component Analysis (PCA) expressing the first two PCAs representing the greatest
variations between the gene expression data and LUAD patient tumor samples from TCGA. Due to external
factors significant variances and confounding batch effects are observed. (b) PCA scatter plot displaying
the first two PCAs representing the greatest variations between the datasets. This included the gene
expression data, shown in green, and LUAD patient tumor samples from TCGA, shown in red, in which
significant confounding variables and variances were observed. (c) The PCA following adjustment and
refinement of gene expression data and patient tumor samples using the ComBat function resulting in
increased data similarity. (d) PCA scatter plot displaying the gene expression data, shown in red and LUAD
patient tumor samples, shown in green, following ComBat adjustment displaying significant improvement
in data similarity and reduction of variances and confounding batch effects.
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(a)

(b)

(c)

Figure 3.1 Gene expression box plots used for gene expression signature validation. (a) Generated box plot
used for validation of BAD displaying the signature’s ability, shown on the x-axis, to distinguish levels of
pathway activity within LUAD patient tumor samples shown on the y-axis. As a result, higher levels of
pathway activity were predicted in 55 samples classified as “HIGH” expressing, while 331 showed
“intermediate” pathway activity, and 155 showed low levels of BAD pathway activation classified as
“LOW” expressing samples. Concluding the signature’s ability to distinguished levels of aberrant activity
with TCGA samples. (b) In this figure, the generated gene expression signature of HER2 predicted higher
levels of pathway activity in 55 patient tumor samples classified as high expressing, 161 intermediate
expressing samples, and 125 low expressing samples distinguishing levels of pathway activity further
validating the signature. (c) Lastly, the gene expression signature of IGF1R was able to distinguish levels
of increased pathway activity within 55 patient tumor samples, classified as “HIGH” expressing, 176 were
identified as “intermediate” expressing, and 310 were characterized as low expressing. In all, validating the
signature’s ability to distinguish accurate levels of pathway activity.
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Figure 4.1 Complex heatmaps generated of optimized gene expression signatures representative of aberrant
pathway activity for the GFRN pathways (a) BAD, 475-gene signature (b) HER2, 5- gene signature
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(c)IGF1R, 25-gene signature (d) RAF, 275-gene signature, and (e) KRAS, 500 gene-signature. The black
bar indicates normal pathway activity or the respective GFRN pathway turned off, expressed using the
HMECs overexpressing GFP (control). The red bar is then used to represent aberrant pathway activity or
pathway activity turned on, generated by the HMECS overexpressing the GFRN-pathways respective
oncogene. Relative to the pathway’s state of activation, genes comprising the signature are shown on the
right expressing varying levels of activity, indicated in red or blue. Genes expressing upregulated levels of
expression are represented in red, and the brighter the red, the higher levels of activity while blue indicates
downregulated levels of activity and the darker the blue, the lower the level of activity.
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